Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

Rhea-AI Summary

Omeros Corporation (Nasdaq: OMER) announced that Gregory A. Demopulos, M.D., CEO, will present at the BofA 2021 Napa BioPharma Virtual Conference on June 15, 2021, at 4:30 p.m. EDT. The presentation will be a fireside chat with analyst Geoff Meacham, PhD. Interested parties can access the live and archived webcast at Omeros Upcoming Events, available for 30 days post-event.

Omeros is focused on developing therapeutics for inflammation and immunologic diseases, with products like OMIDRIA and lead candidate narsoplimab under FDA review.

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT.

The presentation will be webcast. The live and archived webcasts can be accessed at https://investor.omeros.com/upcoming-events. The archived webcast will be available for 30 days.

About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders. Its commercial product OMIDRIA^® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company’s PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros’ pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors. For more information about Omeros and its programs, visit www.omeros.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005362/en/

FAQ

When is Omeros Corporation presenting at the BofA 2021 Napa BioPharma Virtual Conference?

Omeros Corporation is presenting on June 15, 2021, at 4:30 p.m. EDT.

Who will be presenting for Omeros Corporation at the conference?

Gregory A. Demopulos, M.D., the CEO, will be presenting at the conference.

How can I access the Omeros Corporation conference presentation?

The conference presentation can be accessed live and in archive at Omeros' Upcoming Events page.

What is narsoplimab and its significance for Omeros Corporation?

Narsoplimab is Omeros' lead MASP-2 inhibitor, currently under priority review by the FDA for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

What is the stock symbol for Omeros Corporation?

The stock symbol for Omeros Corporation is OMER.